(NASDAQ: OVID) Ovid Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.53%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32%.
Ovid Therapeutics's earnings in 2026 is -$34,492,000.On average, 14 Wall Street analysts forecast OVID's earnings for 2026 to be -$73,822,590, with the lowest OVID earnings forecast at -$78,470,679, and the highest OVID earnings forecast at -$69,721,335. On average, 15 Wall Street analysts forecast OVID's earnings for 2027 to be -$76,810,647, with the lowest OVID earnings forecast at -$101,437,707, and the highest OVID earnings forecast at -$59,468,197.
In 2028, OVID is forecast to generate -$79,232,341 in earnings, with the lowest earnings forecast at -$124,404,735 and the highest earnings forecast at -$20,506,275.